Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reaffirmed at BMO Capital Markets
BMO Capital Markets reiterated their outperform rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report published on Friday. The brokerage currently has a $134.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $99.00.
A number of other brokerages have also weighed in on ALNY. Cowen and Company restated a buy rating and issued a $100.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 11th. Jefferies Group LLC set a $102.00 price objective on Alnylam Pharmaceuticals and gave the company a buy rating in a report on Friday, August 25th. Barclays PLC raised their price objective on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an equal weight rating in a report on Thursday, August 10th. Credit Suisse Group raised their price objective on Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an outperform rating in a report on Tuesday, June 27th. Finally, Leerink Swann restated a market perform rating and issued a $72.00 price objective (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 8th. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of Hold and an average target price of $93.11.
Alnylam Pharmaceuticals (ALNY) traded up 0.78% during midday trading on Friday, reaching $113.80. 2,339,648 shares of the company were exchanged. The stock’s market capitalization is $10.44 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $118.40. The firm’s 50 day moving average price is $81.14 and its 200-day moving average price is $69.12. Alnylam Pharmaceuticals also saw some unusual options trading on Wednesday. Investors acquired 30,530 call options on the company. This represents an increase of approximately 937% compared to the typical daily volume of 2,944 call options.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). The firm had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.05) EPS. Equities analysts forecast that Alnylam Pharmaceuticals will post ($5.19) EPS for the current fiscal year.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Pacer Advisors Inc. grew its position in shares of Alnylam Pharmaceuticals by 22.0% during the second quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 2,093 shares in the last quarter. TLP Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $380,000. Wellington Management Group LLP grew its position in shares of Alnylam Pharmaceuticals by 0.3% during the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after buying an additional 31,208 shares in the last quarter. Hemenway Trust Co LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $235,000. Finally, BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 34,755.2% during the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares in the last quarter. 94.25% of the stock is owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.